What is the optimal nephrology management plan for an adult patient with chronic kidney disease (serum creatinine ~1.6 mg/dL), a history of renal calculi, hypertension (blood pressure 140/90 mm Hg on amlodipine‑thiazide), hypertensive epistaxis, recent urinary‑tract infection, triglycerides 183 mg/dL, and current medications aspirin 75 mg daily and amlodipine‑thiazide?

Nephrology Management Plan for CKD with Hypertension and History of Nephrolithiasis

This patient requires immediate optimization of blood pressure control with addition of an ACE inhibitor or ARB, initiation of an SGLT2 inhibitor for kidney protection, comprehensive metabolic workup including urinalysis with albumin-to-creatinine ratio and eGFR calculation, and evaluation for hereditary causes of nephrolithiasis given the strong family history.

Immediate Diagnostic Workup

Essential Laboratory Studies

• Obtain a complete metabolic panel including serum creatinine, electrolytes, calcium, phosphate, bicarbonate, and calculate eGFR using the CKD-EPI equation without race variable to accurately stage CKD 1.
• Measure serum cystatin C to confirm eGFR, as KDIGO 2024 recommends incorporating cystatin C for more accurate GFR estimation, particularly when creatinine-based estimates may be unreliable 1, 2.
• Obtain a spot urine albumin-to-creatinine ratio (ACR) immediately, as this is essential for CKD staging, risk stratification, and determining eligibility for nephroprotective therapies 1.
• Perform urinalysis with microscopy to assess for hematuria, pyuria, crystals, or other abnormalities that may indicate active stone disease or glomerular pathology 3, 4.
• Check fasting lipid panel (already shows triglycerides 183 mg/dL), hemoglobin A1c to screen for diabetes, complete blood count, parathyroid hormone, 25-hydroxyvitamin D, and uric acid 1, 4.

Stone Disease Evaluation

• Order 24-hour urine collection for volume, calcium, oxalate, citrate, uric acid, sodium, creatinine, and pH to identify metabolic risk factors for recurrent nephrolithiasis, especially given the family history in two daughters suggesting possible hereditary stone disease 3.
• Obtain renal ultrasound to assess for current stones, hydronephrosis, cortical scarring, or asymmetric kidney size that may explain the elevated creatinine 4.
• Consider genetic testing or referral to a stone specialist if metabolic workup reveals cystinuria, primary hyperoxaluria, or other hereditary disorders, particularly given the early-onset stones in both daughters (ages 13 and 17) 3.

Blood Pressure Management

Target Blood Pressure

• Target systolic blood pressure <120 mmHg using standardized office measurement, as the current BP of 140/90 mmHg is above the KDIGO 2021 target for patients with CKD 1, 5.
• If albuminuria ≥30 mg/g is present, the <120 mmHg target becomes even more critical for cardiovascular and kidney protection 1.

Medication Adjustments

• Continue amlodipine-thiazide (Cilacar-T) but recognize that thiazide diuretics may be less effective at eGFR <30 mL/min/1.73 m² and can worsen metabolic abnormalities including hyperuricemia and hypercalciuria, both relevant to stone formation 6.
• Add an ACE inhibitor or ARB immediately, as KDIGO 2024 recommends RAS inhibition for patients with CKD and any degree of albuminuria (A1, A2, or A3), and even for those with normal albuminuria when hypertension is present 1.
• Titrate the ACE inhibitor or ARB to the maximum tolerated dose to achieve the proven benefits demonstrated in clinical trials 1.
• Check serum creatinine and potassium 2-4 weeks after initiating or increasing the dose of ACE inhibitor/ARB; continue therapy unless creatinine rises >30% within 4 weeks 1.
• If thiazide becomes ineffective (eGFR <30 mL/min/1.73 m²), consider switching to a loop diuretic for volume control 6, 7.

Blood Pressure Monitoring

• Implement standardized office blood pressure measurement following guideline-recommended preparations: patient seated quietly for 5 minutes, back supported, feet flat on floor, arm at heart level 1.
• Consider 24-hour ambulatory blood pressure monitoring (ABPM) to confirm office readings and assess for white-coat hypertension or masked hypertension 1.

Nephroprotective Pharmacotherapy

SGLT2 Inhibitor Initiation

• Initiate an SGLT2 inhibitor (dapagliflozin 10 mg daily, empagliflozin 10 mg daily, or canagliflozin 100 mg daily) regardless of diabetes status, as KDIGO 2024 provides a 1A recommendation for adults with CKD and eGFR ≥20 mL/min/1.73 m² when ACR ≥200 mg/g or a 2B recommendation when eGFR 20-45 mL/min/1.73 m² with ACR <200 mg/g 1, 8.
• Do not discontinue SGLT2 inhibitor if eGFR subsequently falls below 20 mL/min/1.73 m² unless not tolerated or kidney replacement therapy is initiated 1.
• Counsel the patient to withhold SGLT2 inhibitor during prolonged fasting, surgery, or critical illness to reduce ketosis risk 1.
• Expect a reversible initial decline in eGFR of 5-10% after SGLT2 inhibitor initiation; this is not an indication to discontinue therapy 1, 2.

Statin Therapy

• Initiate moderate-to-high intensity statin therapy (e.g., atorvastatin 20-40 mg daily or rosuvastatin 10-20 mg daily) for cardiovascular risk reduction, as patients with CKD are at high cardiovascular risk 1, 9, 4.
• Address the elevated triglycerides (183 mg/dL) through dietary modification (low saturated fat, increased omega-3 fatty acids) and consider adding a fibrate or icosapent ethyl if triglycerides remain >200 mg/dL after statin initiation 4.

Consideration of Nonsteroidal MRA

• If albuminuria persists despite maximum tolerated ACE inhibitor/ARB and SGLT2 inhibitor, consider adding finerenone (10 mg daily if eGFR 25-59 mL/min/1.73 m², 20 mg daily if eGFR ≥60 mL/min/1.73 m²) for patients with type 2 diabetes and albuminuria 1, 2.
• Check serum potassium before initiating finerenone (must be ≤4.8 mmol/L) and monitor every 4 weeks initially, then every 4 months 1.

Aspirin Management

Cardiovascular Risk Assessment

• Continue aspirin 75 mg daily for secondary prevention if the patient has established cardiovascular disease (history of myocardial infarction, stroke, or peripheral arterial disease) 9, 4.
• Discontinue aspirin if it is being used for primary prevention, as the bleeding risk in CKD often outweighs the cardiovascular benefit in the absence of established atherosclerotic disease 4.
• Reassess the indication for aspirin by reviewing the patient's cardiovascular history; hypertensive epistaxis suggests increased bleeding risk 6.

Nephrotoxin Avoidance and Medication Review

Nephrotoxin Stewardship

• Discontinue all NSAIDs permanently, as they can precipitate acute-on-chronic kidney injury and worsen hypertension 1, 8, 4.
• Review all over-the-counter medications and supplements for potential nephrotoxins, including proton pump inhibitors (use only when clearly indicated and at the lowest effective dose) 8, 2.
• Avoid iodinated contrast media when possible; if imaging with contrast is essential, ensure adequate hydration and consider N-acetylcysteine prophylaxis, though evidence is mixed 3, 8.
• Adjust doses of all renally cleared medications based on eGFR using validated dosing calculators 1, 2.

Sick Day Medication Management

• Educate the patient to temporarily hold ACE inhibitor/ARB, SGLT2 inhibitor, and diuretics during acute illness with vomiting, diarrhea, or reduced oral intake to prevent acute kidney injury 2.

Metabolic Complications Management

Acidosis Correction

• Check serum bicarbonate; if <22 mEq/L, initiate sodium bicarbonate supplementation (starting at 650 mg three times daily, titrating to maintain bicarbonate 23-29 mEq/L) to slow CKD progression 8.

Hyperkalemia Prevention

• Monitor serum potassium closely after initiating ACE inhibitor/ARB, as the combination with potential SGLT2 inhibitor and existing thiazide creates complex effects on potassium homeostasis 1, 6.
• If hyperkalemia develops (K+ >5.5 mEq/L), implement dietary potassium restriction and consider potassium binders (patiromer or sodium zirconium cyclosilicate) rather than discontinuing nephroprotective RAS inhibition 1.

Mineral Bone Disease Screening

• Monitor calcium, phosphate, PTH, and 25-hydroxyvitamin D levels to detect and treat CKD-mineral bone disorder early 1, 4.
• If phosphate is elevated, initiate dietary phosphate restriction and consider phosphate binders if dietary measures are insufficient 4.
• Correct vitamin D deficiency with ergocalciferol or cholecalciferol before considering active vitamin D analogs 4.

Anemia Evaluation

• Check hemoglobin; if <13 g/dL in men or <12 g/dL in women, evaluate for iron deficiency (serum iron, TIBC, ferritin, transferrin saturation) and consider erythropoiesis-stimulating agents if iron-replete 4.

Stone Disease Prevention

Dietary Modifications

• Increase fluid intake to achieve urine output >2 liters per day to reduce stone recurrence risk 3.
• Implement moderate dietary sodium restriction (<2 g/day), which also benefits blood pressure control and reduces urinary calcium excretion 1, 3.
• Avoid excessive dietary protein (limit to 0.8-1.0 g/kg/day), as high protein intake increases urinary calcium and uric acid excretion 8.
• Ensure adequate dietary calcium intake (1000-1200 mg/day from food sources) rather than restricting calcium, as low calcium intake paradoxically increases oxalate absorption and stone risk 3.

Pharmacologic Stone Prevention

• Based on 24-hour urine results, consider thiazide diuretics for hypercalciuria (though already on thiazide), potassium citrate for hypocitraturia or acidic urine pH, or allopurinol for hyperuricosuria 3.
• Note the potential conflict: thiazide diuretics reduce urinary calcium but may worsen CKD progression and metabolic control; this requires individualized risk-benefit assessment 6.

Monitoring Schedule

Short-Term Follow-Up (First 3 Months)

• Recheck serum creatinine, eGFR, electrolytes, and bicarbonate 2-4 weeks after any medication change (ACE inhibitor/ARB initiation or dose increase, SGLT2 inhibitor initiation) 1.
• Obtain urine ACR at 3 months to assess response to nephroprotective therapy 1.
• Monitor blood pressure weekly at home using a validated automated device and bring readings to follow-up visits 1.

Long-Term Monitoring

• Check serum creatinine, eGFR, electrolytes, and urine ACR every 3-6 months once stable 1, 4.
• Monitor lipid panel, hemoglobin A1c (if diabetic), CBC, calcium, phosphate, PTH, and vitamin D annually 4.
• Repeat 24-hour urine stone risk profile annually if recurrent stone former 3.

Nephrology Referral Criteria

Indications for Urgent Referral

• Refer immediately if eGFR <30 mL/min/1.73 m² to prepare for potential kidney replacement therapy and optimize conservative management 1, 4.
• Refer if albuminuria ≥300 mg/g (A3 category) for consideration of additional nephroprotective interventions 1, 4.
• Refer if eGFR declines >20% over 3-6 months or if there is a sustained rise in creatinine >30% after ACE inhibitor/ARB initiation 1, 4.
• Refer if hypertension remains uncontrolled (>140/90 mmHg) despite 3-4 antihypertensive agents at optimal doses 4.
• Refer for hereditary stone disease evaluation given the strong family history and recurrent stones 3.

Shared Decision-Making About Kidney Replacement Therapy

• Initiate discussions about kidney replacement therapy options (hemodialysis, peritoneal dialysis, kidney transplantation) and conservative management when eGFR approaches 20 mL/min/1.73 m² 9, 4.

Common Pitfalls to Avoid

• Do not discontinue ACE inhibitor/ARB solely because creatinine rises 10-20% after initiation; rises up to 30% within 4 weeks are acceptable and reflect hemodynamic changes rather than kidney injury 1.
• Do not withhold SGLT2 inhibitors in non-diabetic CKD patients; the 2024 KDIGO guidelines provide strong evidence for their use regardless of diabetes status 1.
• Do not attribute all CKD to "hypertensive nephrosclerosis" without confirming the absence of albuminuria, hematuria, or other glomerular disease markers; this patient's history of stones and family history warrants thorough evaluation 3, 4.
• Do not use thiazide diuretics as monotherapy for stone prevention in CKD stage 3b; their efficacy decreases as GFR falls and metabolic side effects may worsen outcomes 6.
• Do not delay statin initiation pending lipid panel optimization; all CKD patients warrant statin therapy for cardiovascular risk reduction regardless of baseline LDL 1, 9.